AstraZeneca showcases cancer drug progress at European Society for Medical Oncology congress in Madrid
AstraZeneca presented multiple cancer research updates during the European Society for Medical Oncology congress held this weekend in Madrid.
Four presentations featured company medicines
Twelve presentations were scheduled for the presidential sessions at the event. Four of those slots included data from AstraZeneca medicines. The company highlighted a mix of existing treatments and new molecules.
Portfolio breadth and data quality noted
Susan Galbraith, head of cancer research and development for the firm, commented on the range of the portfolio. She also pointed to the depth and quality of the data being presented at the meeting.
New combinations and targeted therapies shown
The congress demonstrated the power of combining approved drugs in new ways. Presenters put a spotlight on potential next-generation targeted chemotherapy options that could reach the market soon.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.